CD274 and head and neck squamous cell carcinoma: In the first-line (1L) treatment of r/m PD-L1+ HNSCC, petosemtamab added to standard pembrolizumab therapy demonstrated a 67% confirmed ORR in 24 evaluable patients, with robust responses across PD-L1 tumor levels and human papillomavirus status [57].